benzbromarone |
1 μmol/L |
1 hour |
rat; Sprague–Dawley |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
p < 0.01 |
4 |
benzbromarone |
4 μmol/L |
1 hour |
rat; Sprague–Dawley |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
p < 0.01 |
4 |
benzbromarone |
8 μmol/L |
1 hour |
rat; Sprague–Dawley |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
p < 0.01 |
4 |
benzbromarone |
20 μmol/L |
1 hour |
rat; Sprague–Dawley |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
p < 0.01 |
4 |
Amiodarone |
8 μmol/L |
1 hour |
rat; Sprague–Dawley |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
p < 0.05 |
4 |
Amiodarone |
20 μmol/L |
1 hour |
rat; Sprague–Dawley |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
p < 0.01 |
4 |
benzarone |
8 μmol/L |
1 hour |
rat; Sprague–Dawley |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
p < 0.01 |
4 |
benzarone |
20 μmol/L |
1 hour |
rat; Sprague–Dawley |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
p < 0.01 |
4 |
Diclofenac |
50 μmol/L |
3 minutes |
rat |
liver mitochondria |
Assessment of Mitochondrial Membrane Potential; incubated in the presence of Ca2+ |
decrease |
Positive |
p < 0.01 |
6 |
Diclofenac |
250 μmol/L |
24 hours |
rat |
hepatocytes |
Assessment of Mitochondrial Membrane Potential |
decrease |
Positive |
p < 0.01 |
6 |
Diclofenac |
500 μmol/L |
24 hours |
rat |
hepatocytes |
Assessment of Mitochondrial Membrane Potential |
decrease |
Positive |
p < 0.01 |
6 |
Metformin |
1 mM |
24 hours |
human |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
|
15 |
Metformin |
2 mM |
24 hours |
human |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
|
15 |
buformin |
75 μM |
24 hours |
human |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
|
15 |
Phenformin |
12.5 μM |
24 hours |
human |
hepatocytes |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
|
15 |
Perhexiline |
200 μM |
|
mouse; Crl/CD-l(1CR)BR Swiss |
liver mitochondria |
Measurement of mitochondrial membrane potential |
decrease |
Positive |
|
193 |
(1,1,3,3-tetramethylbutyl)phenol |
2.85±0.86 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(1'-ethyl-6,7-dihydro-5h-spiro[furo[2,3-f]indole-3,4'-piperidin]-5-yl)[2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl]methanone hydrochloride |
6.09±2.54 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(2-ethyl-4-{[(4-{[4-(4-methoxyphenyl)piperazin-1-yl]methyl}-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]sulfanyl}phenoxy)acetic acid |
25.29±5.81 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(2-nitro-1-propenyl)benzene |
38.57±15.32 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(5-chloro-2-hydroxyphenyl)phenylmethanone |
29.09±3.36 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(5s,8s)-5-(3,4-dichlorophenyl)-8-(methylamino)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide |
8.31±1.43 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(9z)-octadec-9-enamide |
41.61±7.16 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(acryloyloxy)(tributyl)stannane |
0.19±0.11 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(n-6)-methyladenine |
5.98±5.84 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-(2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalen-2-yl)ethanone |
27.31±20.44 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-(3,5,5,6,8,8-hexamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethanone |
30.64±18.87 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,1,1-trichloropropanone |
1.22±0.56 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,1,2-trimethyl-1h-benzo[e]indole |
23.42±4.03 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,1':3',1''-terphenyl |
47.88±14.29 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,2,5,6,9,10-hexabromocyclododecane |
6.93±1.95 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,2-benzisothiazolin-3-one |
38.57±13.65 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,2-phenylenediamine |
3.90±3.61 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,2-phenylenediamine dihydrochloride |
0.44±0.20 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3,5-tris(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-1,3,5-triazinane-2,4,6-trione |
12.20±2.84 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3-didecyl-2-methylimidazolium chloride |
3.86±4.19 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3-diiminobenz(f)isoindoline |
11.08±7.81 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3-diphenyl-1,3-propanedione |
11.68±1.35 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,4-benzenediamine |
3.28±0.42 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,4-diaminoanthraquinone |
0.03±0.01 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,4-dihydroxyanthracene-9,10-dione |
5.24±3.43 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,4-naphthalenediamine |
0.20±0.08 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,5-naphthalenediamine |
17.00±19.61 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,8-dihydroxy-4,5-dinitroanthraquinone |
0.07±0.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
10-chloro-9-anthraldehyde |
13.87±7.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Mito-4509 |
37.81±13.89 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
17alpha-ethinylestradiol |
19.12±5.99 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-amino-2,4-dibromoanthraquinone |
2.78±3.75 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-amino-2-methylanthraquinone |
0.64±0.08 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-benzyl-1-{[3-(4-chlorophenyl)-5-methyl-1-benzofuran-2-yl]methyl}-3-(2,4,6-trifluorophenyl)urea |
21.01±2.43 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-decyl-3-methylimidazolium tetrafluoroborate |
3.87±16.67 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-decyl-3-methylimidazolium trifluoromethanesulfonate |
1.67±2.71 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-dodecyl-3-methylimidazolium hexafluorophosphate |
3.71±8.52 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-fluoro-2,4-dinitrobenzene |
3.71±0.60 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1h,3h-naphtho(1,8-cd)pyran-1,3-dione |
3.89±1.12 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1h-benzo[de]isoquinoline-1,3(2h)-dione |
8.31±3.47 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1h-indole-2-carboxamide, n-[(3r)-1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- |
8.41±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-hydroxypyrene |
4.67±1.95 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-isocyanato-3-(trifluoromethyl)benzene |
3.28±1.13 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methyl-3-octylimidazolium hexafluorophosphate |
8.23±5.05 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methyl-3-octylimidazolium tetrafluoroborate |
5.66±5.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methyl-3-octylimidazolium trifluoromethanesulfonate |
8.38±4.29 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methylpyrene |
43.23±4.99 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-naphthol |
31.04±5.96 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-nitronaphthalene |
59.74±7.06 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-nitropyrene |
2.01±2.06 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Edaravone |
31.75±4.28 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-trans-delta-9-tetrahydrocannabinol |
4.99±1.66 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-(4-hydroxybenzyl)phenol |
27.47±1.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-(butan-2-yl)phenol |
49.48±9.45 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-(thiocyanomethylthio)benzothiazole |
33.08±4.58 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2',4,4',5-pentabromodiphenyl ether |
8.00±3.19 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2',6,6'-tetrachlorobisphenol a |
4.86±3.13 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'4,4'-tetrabromodiphenyl ether |
22.56±5.18 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane |
8.78±1.43 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2-bis[(benzoyloxy)methyl]dibenzoate propanediol |
4.32±8.63 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-dichlorobiphenyl |
31.09±12.28 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-dihydroxy-4,4'-dimethoxybenzophenone |
7.75±1.80 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-dihydroxy-4-methoxybenzophenone |
9.89±1.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-methylenebis(4-methyl-6-tert-butylphenol) |
1.35±0.26 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-methylenebis(ethyl-6-tert-butylphenol) |
1.22±0.73 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3',4,4'-tetrahydroxybenzophenone |
7.39±7.14 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,4,5-tetrachlorophenol |
4.93±2.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,4-trichlorophenol |
5.23±1.52 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,5,6-tetrachlorophenol |
6.42±2.38 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,5-trichlorophenol |
5.80±1.05 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4,5-trichlorophenol sodium salt |
5.05±2.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4,6-trinitro-1,3-dimethyl-5-tert-butylbenzene |
20.09±6.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-bis(1-methyl-1-phenylethyl)phenol |
3.49±1.51 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-diaminoanisole sulfate |
2.51±1.16 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-diaminophenol dihydrochloride |
3.77±1.06 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-dichloro-3,5-dimethylphenol |
5.88±4.85 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-diisopropylphenol |
17.23±1.99 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-di-tert-butylphenol |
3.50±0.73 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,5-bis(2-methylbutan-2-yl)benzene-1,4-diol |
6.86±3.17 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,5-di-tert-butylbenzene-1,4-diol |
7.41±1.27 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-bis-(1,1-dimethylethyl)-2,5-cyclohexadiene-1,4-dione |
18.60±12.40 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-di(butan-2-yl)phenol |
13.69±3.19 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-diaminopyridine |
31.28±10.35 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-di-tert-butyl-4-nitrophenol |
0.17±0.05 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-toluenediamine |
15.70±10.03 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
24r,25-dihydroxyvitamin d3 |
13.02±2.17 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-Acetylaminofluorene |
36.27±10.50 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4-(p-nitrophenyl)thiazole |
3.90±1.78 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4,6-dinitrophenol |
4.18±2.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4-chloro-5-nitrophenol |
21.51±2.48 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4-chlorobenzothiazole |
29.57±5.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-5-nitrophenol |
27.40±14.08 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-6-nitrobenzothiazole |
12.69±10.45 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-aminoanthracene |
4.71±1.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-aminoanthraquinone |
0.51±0.29 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-chloro-4-phenylphenol |
15.36±7.86 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-dodecylisoquinolinium tosylate |
3.53±0.50 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydrazino-4-(4-aminophenyl) thiazole |
0.06±0.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydrazino-4-(4-nitrophenyl)thiazole |
1.60±0.29 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydrazino-4-phenylthiazole |
2.32±0.79 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydroxyanthraquinone |
3.31±1.38 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-isovaleryl-1,3-indanedione |
5.24±0.90 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-methyl-1-nitroanthraquinone |
1.34±0.15 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-methylanthraquinone |
6.33±1.15 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-naphthalenesulfonic acid, 7-amino-4-hydroxy- |
27.33±3.73 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-naphthalenol |
50.10±16.03 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-nitro-1,4-phenylenediamine |
7.07±6.53 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-nitrofluorene |
12.19±0.86 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-pentylfuran |
42.19±2.81 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-phenylphenol |
17.90±1.41 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-propenal,3,3-diphenyl- |
41.19±19.34 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-tert-butyl-4-ethylphenol |
11.30±2.60 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-tert-butyl-4-methoxyphenol |
25.29±1.71 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-tert-butyl-5-methylphenol |
23.48±2.85 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexanol |
31.84±17.54 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3',4,4'-tetraaminobiphenyl tetrahydrochloride |
0.34±0.26 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3',5,5'-tetraiodothyroacetic acid |
45.79±2.99 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3'-diaminobenzidine |
13.69±14.86 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3'-dimethylbisphenol a |
8.88±3.37 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3φ,5,5φ-tetrabromobisphenol a |
13.23±12.24 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,4,5-trichlorophenol |
3.80±1.74 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,4-dichlorophenol |
9.18±2.63 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,5-dichlorophenol |
9.79±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,5-dichlorosalicyl-3,4-dichloroanilide |
0.22±0.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-acetylphenanthrene |
36.89±13.68 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-amino-9-ethylcarbazole hydrochloride |
35.36±24.49 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-hydroxybenzophenone |
27.72±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-hydroxy-n-(3-nitrophenyl)naphthalene-2-carboxamide |
0.24±0.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-hydroxy-n-phenylaniline |
28.48±6.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-methylbenzene-1,2-diamine |
21.74±3.65 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-methylcholanthrene |
17.26±13.23 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-methyl-n-phenylaniline |
48.56±5.61 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(1,1,3,3-tetramethylbutyl)phenol |
4.25±0.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(2-methylbutan-2-yl)phenol |
22.71±3.07 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(3-phenylpropyl)pyridine |
16.58±6.74 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(benzyloxyl)phenol |
18.46±1.51 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(butan-2-yl)phenol |
31.98±3.64 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4,4-trifluoro-1-phenyl-1,3-butanedione |
20.37±6.17 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-diaminoazobenzene |
10.45±3.59 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-diaminobenzanilide |
3.72±2.85 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-dichlorodiphenyl sulfone |
21.27±6.06 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-dinitrodiphenylurea |
0.46±0.06 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-methylenebis(2-chloroaniline) |
49.14±17.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-sulfonylbis[2-(prop-2-en-1-yl)phenol] |
44.97±17.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-thiobis(6-tert-butyl-m-cresol) |
1.86±1.18 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-thiodiphenol |
21.08±2.70 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,6-dichloro-1,3-benzenediol |
9.55±2.74 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,6-di-tert-butyl-m-cresol |
2.25±1.49 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-amino-2,6-dichlorophenol |
17.23±13.38 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-amino-2-nitrophenol |
15.42±10.56 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-amino-4φ-hydroxy-3-methyldiphenylamine |
7.66±0.88 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-benzylphenol |
15.94±3.38 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-chloro-1,2-diaminobenzene |
2.38±1.60 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-chloro-2-cyclopentylphenol |
5.66±1.93 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-chloro-3,5-dimethylphenol |
21.00±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-chlorophenyl isocyanate |
0.27±0.11 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-cumylphenol |
3.70±0.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4'-demethylepipodophyllotoxin |
2.66±3.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-dodecylphenol |
3.18±0.58 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-hexyl-4'-cyanobiphenyl |
42.53±15.42 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-hydroxybenzophenone |
41.31±18.12 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-methyl-2,6-dinitrophenol |
26.55±4.57 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-nitroanthranilic acid |
38.57±17.22 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-nitro-n-phenylaniline |
7.43±6.54 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-nitrosophenol |
4.71±2.31 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-octyloxybenzoic acid |
39.63±31.34 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-octylphenol |
8.77±2.96 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-phenoxyphenol |
27.97±10.62 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-styrylpyridine |
11.22±5.54 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-tert-butylcatechol |
34.27±14.96 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-tert-butylphenyl salicylate |
28.37±3.64 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
5,7-dichloro-8-hydroxy-2-methylquinoline |
11.01±2.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
5alpha-dihydrotestosterone |
13.30±6.16 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
5hpp-33 |
2.09±0.87 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Busulfan |
14.43±5.99 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
5-nitroacenaphthene |
34.38±20.44 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
6-hydroxy-2-naphthyl disulfide |
33.74±3.64 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
6-nitrobenzimidazole |
36.41±10.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
6-nitroquinoline |
30.73±11.46 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9,10-dihydrobenzo[a]pyren-7(8h)-one |
9.81±2.08 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-aminoacridine, monohydrochloride, monohydrate |
13.80±1.75 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-anthracenemethanol |
34.48±11.46 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-cyanoanthracene |
6.85±18.05 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-nitroanthracene |
21.44±12.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-phenanthrol |
1.22±0.56 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
acenocoumarol |
8.36±1.07 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
acetaldehyde |
18.02±6.38 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aclarubicin hydrochloride |
3.15±2.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
acriflavine hydrochloride |
0.94±0.44 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Albendazole |
9.35±1.83 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aldrin |
31.20±7.21 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
alizarin |
11.01±1.41 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
allylestrenol |
12.83±3.68 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aloe-emodin |
1.79±1.54 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
alpha-1,2,3,4,5,6-hexachlorocyclohexane |
49.00±6.35 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
alpha-amylcinnamyl alcohol |
38.11±17.40 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ambazone |
5.60±3.23 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ami-193 |
5.82±3.05 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aminoquinuride dihydrochloride |
25.01±4.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
amorolfine |
21.61±3.47 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
amsacrine hydrochloride |
10.34±2.45 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
amylmetacresol |
11.17±0.65 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
anthrone |
21.84±9.90 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
apigenin |
1.61±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aranidipine |
12.83±3.68 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aroclor 1260 |
21.47±2.75 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
arotinolol hydrochloride |
17.04±3.45 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
axitinib |
3.76±2.80 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
barban |
22.54±4.10 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bardoxolone methyl |
5.11±1.27 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
barium bis(2-ethylhexanoate) |
15.36±10.31 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
barium chloride |
16.58±8.50 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
basic blue 7 |
0.02±0.03 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bazedoxifene |
11.01±0.75 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
beclazone |
23.71±2.74 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzbromarone |
7.22±1.24 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzidine |
24.34±4.50 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benziodarone |
2.98±0.63 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzobarbital |
24.07±5.12 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzoic acid, 2-[(4-chloro-3-methylphenyl)amino]- |
12.83±0.84 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzyldimethyltetradecylammonium chloride dihydrate |
16.40±4.28 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzyldodecyldimethylammonium bromide |
11.44±4.34 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzylhydrazine dihydrochloride |
27.81±3.21 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
berberine chloride |
2.03±1.29 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
betamethasone dipropionate |
25.60±1.67 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bexarotene |
16.49±3.95 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bis(tributyltin)oxide |
0.09±0.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisacodyl |
14.82±3.63 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Bisphenol A |
13.97±6.29 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol a glycidyl methacrylate |
12.20±11.86 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol af |
5.44±1.42 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol b |
10.66±2.48 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol e |
27.64±1.80 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol z |
22.19±5.51 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bithionol |
0.66±0.52 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bosutinib |
0.75±0.48 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromadiolone |
16.67±1.13 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromociclen |
33.18±3.47 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromocriptine |
11.44±1.58 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromocriptine mesylate |
11.19±2.78 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromofenoxim |
1.08±0.25 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromofos |
7.70±1.63 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromoxynil octanoate |
15.29±5.08 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
broquinaldol |
26.60±4.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bryostatin 1 |
0.01±0.01 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
buclizine dihydrochloride |
32.23±2.10 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
butylparaben |
19.00±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. 1040 |
8.10±1.39 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. basic orange 2 |
7.53±5.61 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. basic red 9 monohydrochloride |
0.08±0.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. basic violet 14 |
0.18±0.16 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. disperse blue 27 |
2.34±0.87 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. solvent yellow 14 |
5.84±2.06 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
calcifediol |
5.82±0.47 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
calcipotriene |
25.98±3.89 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
calcitriol |
14.06±4.15 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
candesartan cilexetil |
15.94±4.62 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cannabinol |
1.68±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cantharidin |
0.15±0.08 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
CCCP |
0.15±0.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
carminomycin |
1.25±0.73 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfenapyr |
0.07±0.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfenethol |
26.28±7.53 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfenson |
38.83±25.41 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfluazuron |
8.93±4.57 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorophacinone |
0.64±0.25 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chloropropylate |
26.28±3.64 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chloroxine |
10.59±1.22 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chromomycin |
12.35±0.84 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chrysarobin |
22.82±3.93 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chrysin |
5.05±2.76 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ciclesonide |
7.91±1.38 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Ciglitazone |
8.22±1.60 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cilnidipine |
12.53±1.78 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cinalukast |
28.81±1.17 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
clobetasol |
14.40±3.67 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
clobetasol propionate |
24.64±1.67 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cloflucarban |
0.60±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
clofoctol |
1.64±0.13 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
clonixin |
19.86±6.75 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cloxyquin |
16.79±5.94 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
coumatetralyl |
13.69±4.84 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cresyl diphenyl phosphate |
2.38±2.32 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
curcumin |
1.31±1.03 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cybutryne |
20.87±13.91 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cyclododecanol |
48.78±3.84 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cyhalothrin |
33.62±5.79 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
d&c yellow 11 |
0.38±0.13 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
danthron |
4.66±1.19 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dantrolene sodium |
4.35±1.73 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
darbufelone mesylate |
11.74±2.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
deltamethrin |
45.88±17.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
deslanoside |
1.84±0.23 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
desogestrel |
22.29±2.11 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
devazepide |
12.53±5.62 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dexamethasone valerate |
12.06±4.39 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diacerein |
20.64±8.26 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dianiline |
18.40±5.73 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dichlofluanid |
5.24±1.99 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dichlorodiphenylsilane |
12.96±9.66 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diclazuril |
11.17±2.79 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dicofol |
9.69±3.51 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
N,N'-dicyclohexylcarbodiimide |
0.30±0.20 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dienestrol |
10.93±1.88 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Diethylstilbestrol |
9.76±6.25 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diethylstilbestrol dipropionate |
10.46±2.66 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diflorasone diacetate |
28.73±1.87 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
digitoxin |
0.16±0.05 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
digoxin |
0.52±0.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dihydrotachysterol |
32.71±1.32 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinex |
0.28±0.34 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diniconazole |
12.18±3.53 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinobuton |
4.33±1.24 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinocap |
0.34±0.30 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinoterb |
0.48±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diphenan |
22.29±4.67 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diphenoxylate hydrochloride |
20.65±1.19 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diphenylcyclopropenone |
25.60±1.67 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diphenylurea |
1.60±0.74 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
disperse red 82 |
8.00±1.45 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dithiazanine chloride |
0.27±0.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dithiazanine iodide |
0.10±0.15 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
docetaxel |
14.96±29.77 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dodecyl gallate |
4.75±1.81 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dodecylparaben |
4.19±1.07 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dodecylphenol |
3.10±1.22 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
doramapimod;bibr-796? |
21.13±5.52 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
doramectin |
11.88±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ebselen |
23.16±0.93 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
emodin |
1.33±0.78 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
endosulfan sulfate |
15.96±2.05 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
endrin |
23.52±7.96 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
enterolactone |
9.99±5.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
eprinomectin (b1a, b1b mixture) |
4.22±0.90 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
equilin |
24.34±4.60 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ergotamine d-tartrate |
7.55±1.06 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
estradiol acetate |
9.08±0.59 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethacridine lactate hydrate |
3.22±0.55 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethalfluralin |
43.28±17.60 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethanol, 2,2'-((1-methylethylidene)bis((2,6-dibromo-4,1-phenylene)oxy))bis- |
6.21±0.42 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethoxazene |
2.70±1.13 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethyl linolenate |
49.65±36.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethynodiol diacetate |
15.40±0.84 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
etocarlide |
17.04±6.52 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
everolimus |
19.86±2.83 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
exalamide |
9.81±3.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ezetimibe |
25.60±3.54 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
famoxadone |
4.19±1.07 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenamidone |
43.28±17.10 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenarimol |
42.59±21.91 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenchlorphos |
13.62±2.52 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fendiline hydrochloride |
10.34±1.55 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenhexamid |
8.31±1.15 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenobam |
25.85±1.87 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenretinide |
3.40±0.76 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fentiazac |
27.43±2.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenticlor |
2.15±0.36 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenvalerate |
32.06±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
flopropione |
18.83±6.83 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluazuron |
3.96±2.31 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
flubendiamide |
18.72±2.59 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
flucythrinate |
35.72±20.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Flufenamic Acid |
36.64±1.87 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
flunixin meglumine |
9.02±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluorodifen |
27.31±25.06 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluorosalan |
0.24±0.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluoxastrobin |
45.79±15.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluticasone propionate |
9.02±1.71 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluvastatin |
27.64±1.87 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
folpet |
8.25±0.54 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
forchlorfenuron |
0.45±0.13 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
formononetin |
13.17±4.88 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fulvestrant |
5.86±0.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
geliomycin |
0.52±0.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
genistein |
6.34±0.77 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
gentian violet |
0.08±0.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
glycyrrhetinic acid |
40.10±9.34 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
gramicidin |
0.51±0.42 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
halobetasol propionate |
15.18±5.52 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
heptachlor |
39.40±17.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Hexachlorophene |
0.70±0.46 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
hydroxystilbamidine bis(methanesulfonate) |
2.81±0.90 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
idarubicin hydrochloride |
6.83±1.46 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
idazoxan |
20.64±7.46 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
indole-3-pyruvic acid |
28.92±16.69 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
indoxacarb |
12.73±3.65 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
iodophthalein |
5.31±1.76 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
iodophthalein sodium |
10.75±3.91 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
isobutylparaben |
14.21±1.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
isodrin |
43.28±15.32 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
isoxaben |
26.32±5.75 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
isoxicam |
5.18±2.90 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
israpafant |
21.96±1.49 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
kaempferol |
2.56±3.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
kepone |
0.93±0.65 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Ketoconazole |
10.81±3.25 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lambda-cyhalothrin |
24.35±1.59 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lanatoside a |
0.43±0.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lanatoside b |
1.10±0.20 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lanatoside c |
0.78±0.14 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lapachol |
26.12±1.70 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lasalocid sodium |
1.14±0.07 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lercanidipine hydrochloride |
6.53±0.53 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lestaurtinib |
4.80±0.97 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lopinavir |
32.71±1.32 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lornoxicam |
9.44±1.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lufenuron |
7.65±0.70 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lynestrenol |
16.63±2.15 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lysergide |
9.03±1.87 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
malachite green oxalate |
2.10±1.87 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
malotilate |
14.96±1.99 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
manidipine |
12.15±6.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Mebendazole |
2.45±0.34 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Meloxicam |
14.47±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mepartricin |
23.16±6.59 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mepronil |
40.86±19.18 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mesotrione |
17.97±11.96 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
metanixin |
25.98±2.11 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methfuroxam |
25.78±1.71 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methisazone |
5.82±1.38 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Methoxychlor |
26.28±8.69 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyl 2,4-dihydroxy-3,6-dimethylbenzoate |
15.96±6.62 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyl triclosan |
25.53±1.67 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyl violet |
0.07±0.03 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyldigoxin |
0.73±0.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Methylene Blue |
2.88±1.33 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methylene blue trihydrate |
1.31±0.79 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methylsilanetriyl triacetate |
29.07±16.38 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyltrioctylammonium trifluoromethanesulfonate |
2.16±0.72 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
metochalcone |
18.18±10.11 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mgk-264 |
15.36±10.52 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mifepristone |
16.13±32.54 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
miripirium chloride |
16.40±4.01 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mk-2206 |
17.78±7.38 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mometasone furoate |
11.80±0.80 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
montelukast sodium |
32.71±1.32 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n,n-diethylbenzene-1,4-diamine |
49.89±3.51 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n,n-dimethyl-p-phenylenediamine |
9.10±0.59 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n,nφ-diethylcarbanilide |
21.69±38.23 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide |
14.78±9.66 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n-cyclohexyl-4-methyl benzenesulfonamide |
36.15±20.97 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nelfinavir mesylate |
11.88±6.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Niclosamide |
0.03±0.01 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
niflumic acid |
13.02±2.17 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nifuroxazide |
1.57±0.30 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Nimesulide |
3.87±0.23 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ninhydrin |
32.00±9.69 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Nitazoxanide |
1.04±0.96 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Nitrofurantoin |
26.31±6.35 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nitrovin |
3.27±0.57 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nitroxoline |
9.22±2.41 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n-methyl-n,n-dioctyloctan-1-aminium chloride |
2.73±0.32 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nocodazole |
3.53±1.63 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nonylparaben |
4.43±0.30 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
norelgestromin |
13.53±6.64 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
noristerat |
9.81±1.78 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n-phenyl-1,4-benzenediamine hydrochloride |
5.82±6.96 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
o,p'-ddd |
19.83±0.94 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
o,p'-ddt |
23.98±12.11 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
olvanil |
13.53±1.90 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
osalmid |
6.68±0.77 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ouabain |
0.18±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
oxyphenisatin acetate |
5.49±4.60 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
p,p'-ddd |
15.19±8.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
p,p'-dde |
25.60±1.71 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
p,p'-ddt |
24.26±2.74 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
palmatine chloride hydrate |
22.74±5.23 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
paricalcitol |
8.91±1.56 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
p-benzoquinone dioxime |
43.30±14.86 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
penfluridol |
33.49±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2',4,4',5-pentabromodiphenyl ether |
15.46±7.01 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pentabromophenol |
3.46±0.99 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Pentachlorophenol |
3.09±0.60 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pentylparaben |
8.74±1.65 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
perfluorooctanesulfonamide |
2.43±0.81 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenazopyridine hydrochloride |
15.72±3.45 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenmedipham |
4.41±2.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenol, 4,4'-butylidenebis[2-(1,1-dimethylethyl)-5-methyl- |
5.51±1.58 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenol, 4-methyl-, reaction products with dicyclopentadiene and isobutylene |
15.55±8.56 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenolphthalein |
42.78±2.74 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenoxybenzamine hydrochloride |
48.80±9.17 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenyl isothiocyanate |
43.01±14.76 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phloretin |
4.26±1.22 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
picoxystrobin |
9.31±2.67 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
picropodophyllin |
0.14±0.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pinacyanol |
0.01±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pirarubicin |
0.60±0.46 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pirenoxine sodium |
21.13±17.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Piroxicam |
8.21±1.71 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
polyethylene glycol (9z)-9-octadecenyl ether |
7.50±18.45 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
polyoxyethylene(10)nonylphenyl ether |
10.20±6.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
p-phenylazophenol |
4.06±1.23 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
prodiamine |
4.84±0.56 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
profenofos |
2.54±1.84 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
proflavin hemisulfate |
3.22±0.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
proflavin hydrochloride |
1.66±0.63 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
profluralin |
21.69±8.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
propan-2-yl (2r,4s)-4-{acetyl[3,5-bis(trifluoromethyl)benzyl]amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate |
5.66±1.72 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
propyl gallate |
42.29±3.93 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
propylparaben |
38.60±1.67 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
proscillaridin |
0.09±0.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyraclostrobin |
6.35±1.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyridate |
33.08±4.58 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyrinuron |
26.28±1.71 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyrvinium pamoate |
2.02±1.20 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
quercetin |
2.69±2.26 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
quercetin dihydrate |
6.20±2.32 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rac benidipine hydrochloride |
14.96±3.18 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rafoxanide |
3.27±1.76 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
raloxifene |
5.05±3.99 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
raloxifene hydrochloride |
6.69±1.65 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
resveratrol |
1.60±0.43 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Rhein |
6.06±5.91 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
riboflavin |
7.02±1.78 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rifampicin |
25.06±6.38 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rifapentine |
1.46±0.26 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rimonabant |
25.60±1.67 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rolicyclidine |
22.29±2.32 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Rotenone |
17.38±1.94 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
salicylanilide |
3.71±1.27 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
selenious acid |
15.97±22.77 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
siduron |
41.65±21.12 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
silwet l77 |
5.66±1.03 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rapamycin |
20.08±2.07 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sodium (4-fluoro-2-{[(1s)-1-phenylpropyl]carbamoyl}phenyl)(quinolin-8-ylsulfonyl)azanide |
4.42±6.97 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sodium 2-phenylphenate tetrahydrate |
18.53±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sodium bithionolate |
0.91±0.78 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sodium warfarin |
38.57±12.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sofalcone |
24.64±1.67 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sorafenib |
0.96±0.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sp600125 |
0.92±0.14 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
spiclomazine hydrochloride |
34.80±2.36 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
spiperone |
3.62±0.24 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
su-5416 |
12.53±1.78 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sulfanitran |
26.60±8.77 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
surinabant |
33.08±16.61 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
talniflumate |
27.00±2.56 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tamibarotene |
25.68±1.05 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tamsulosin hydrochloride |
27.20±2.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tau-fluvalinate |
37.16±15.12 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenidap |
12.53±1.19 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenonitrozole |
0.73±0.12 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenovin-1 |
3.27±2.74 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenoxicam |
8.36±1.07 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tert-butyl 4-hydroxybenzoate |
25.29±7.32 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetra-aminopyrimidine sulfate |
18.70±11.39 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetrabromophenolphthalein ethyl ester |
23.80±6.89 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetrabutyltin |
5.66±1.03 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetradecylpyridinium bromide |
22.54±4.10 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetradifon |
15.34±7.43 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetraiodoethene |
5.45±1.27 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetra-n-octylammonium bromide |
0.13±0.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetraoctylphosphonium bromide |
0.18±0.12 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetrasul |
1.77±0.25 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
thidiazuron |
3.43±0.73 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
thiram |
1.94±25.92 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tibrofan |
0.79±0.11 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tioxidazole |
7.50±1.75 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Tipranavir |
26.60±4.94 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tolclofos-methyl |
30.64±5.80 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Tolfenamic Acid |
11.88±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
toluidine blue |
3.48±1.60 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tolvaptan |
17.44±8.01 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
transfluthrin |
25.01±4.09 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tribenoside |
11.80±0.80 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tribromosalan |
1.12±0.00 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltetradecylphosphonium chloride |
0.71±0.15 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltin benzoate |
0.15±0.23 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltin chloride |
0.11±0.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltin methacrylate |
0.07±0.01 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tricirbine |
1.21±1.51 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triclabendazole |
1.84±0.15 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triclocarban |
0.14±0.05 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triclosan |
1.50±0.88 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triethoxy(2-methylpropyl)silane |
28.92±6.98 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triethyltin bromide |
0.02±0.02 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trifluralin |
46.68±9.14 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trihexyltetradecylphosphonium bromide |
0.84±0.24 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trihexyltetradecylphosphonium chloride |
0.77±0.35 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trihexyltetradecylphosphonium dicyanamide |
0.39±0.19 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trihexyltetradecylphosphonium hexafluorophosphate |
0.43±0.17 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyl phosphate |
1.38±1.48 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenylethylene |
35.72±14.82 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyltin acetate |
0.12±0.04 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyltin fluoride |
0.47±0.31 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyltin hydroxide |
0.12±0.03 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tris(2,3-dibromopropyl) phosphate |
45.81±8.72 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Tyrothricin |
0.24±0.05 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tyrphostin 23 |
17.70±6.46 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
vatalanib |
25.60±4.41 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Verteporfin |
3.27±1.85 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
zafirlukast |
10.59±1.22 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
zearalenone |
4.67±1.77 |
|
human |
qHTS-HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(1,1,3,3-tetramethylbutyl)phenol |
3.98 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(1'-ethyl-6,7-dihydro-5h-spiro[furo[2,3-f]indole-3,4'-piperidin]-5-yl)[2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl]methanone hydrochloride |
19.95 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(2-ethyl-4-{[(4-{[4-(4-methoxyphenyl)piperazin-1-yl]methyl}-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]sulfanyl}phenoxy)acetic acid |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(5-chloro-2-hydroxyphenyl)phenylmethanone |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(5s,8s)-5-(3,4-dichlorophenyl)-8-(methylamino)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide |
10 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(acryloyloxy)(tributyl)stannane |
0.4 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(n-6)-methyladenine |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Diethylstilbestrol |
5.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-(2,3,8,8-tetramethyl-1,2,3,4,5,6,7,8-octahydronaphthalen-2-yl)ethanone |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-(3,5,5,6,8,8-hexamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethanone |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,1,1-trichloropropanone |
3.16 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,1,2-trimethyl-1h-benzo[e]indole |
10 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,1':3',1''-terphenyl |
50.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,2,5,6,9,10-hexabromocyclododecane |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,2-benzisothiazolin-3-one |
17.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,2-phenylenediamine |
2.51 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,2-phenylenediamine dihydrochloride |
1.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3,5-tris(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-1,3,5-triazinane-2,4,6-trione |
44.67 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3-didecyl-2-methylimidazolium chloride |
3.16 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3-diiminobenz(f)isoindoline |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3-diphenyl-1,3-propanedione |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,4-benzenediamine |
2.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,4-diaminoanthraquinone |
0.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,4-dihydroxyanthracene-9,10-dione |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,4-naphthalenediamine |
2 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,5-naphthalenediamine |
3.16 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,8-dihydroxy-4,5-dinitroanthraquinone |
0.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Mito-4509 |
22.39 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
17alpha-ethinylestradiol |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-amino-2-methylanthraquinone |
2.51 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-benzyl-1-{[3-(4-chlorophenyl)-5-methyl-1-benzofuran-2-yl]methyl}-3-(2,4,6-trifluorophenyl)urea |
56.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-decyl-3-methylimidazolium tetrafluoroborate |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-decyl-3-methylimidazolium trifluoromethanesulfonate |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-dodecyl-3-methylimidazolium hexafluorophosphate |
5.01 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-fluoro-2,4-dinitrobenzene |
5.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1h,3h-naphtho(1,8-cd)pyran-1,3-dione |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1h-benzo[de]isoquinoline-1,3(2h)-dione |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1h-indole-2-carboxamide, n-[(3r)-1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- |
13.77 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-hydroxypyrene |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-isocyanato-3-(trifluoromethyl)benzene |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methyl-3-octylimidazolium hexafluorophosphate |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methyl-3-octylimidazolium tetrafluoroborate |
19.95 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methyl-3-octylimidazolium trifluoromethanesulfonate |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methylpyrene |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-naphthol |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-nitropyrene |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Edaravone |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-trans-delta-9-tetrahydrocannabinol |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-(4-hydroxybenzyl)phenol |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-(butan-2-yl)phenol |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-(thiocyanomethylthio)benzothiazole |
56.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2',4,4',5-pentabromodiphenyl ether |
4.47 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2',6,6'-tetrachlorobisphenol a |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'4,4'-tetrabromodiphenyl ether |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane |
10 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2-bis[(benzoyloxy)methyl]dibenzoate propanediol |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-dichlorobiphenyl |
63.1 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-dihydroxy-4,4'-dimethoxybenzophenone |
12.59 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-dihydroxy-4-methoxybenzophenone |
5.24 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-methylenebis(4-methyl-6-tert-butylphenol) |
2 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-methylenebis(ethyl-6-tert-butylphenol) |
2 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3',4,4'-tetrahydroxybenzophenone |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,4,5-tetrachlorophenol |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,4-trichlorophenol |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,5,6-tetrachlorophenol |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,5-trichlorophenol |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4,5-trichlorophenol sodium salt |
10 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4,6-trinitro-1,3-dimethyl-5-tert-butylbenzene |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-bis(1-methyl-1-phenylethyl)phenol |
2.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-diaminoanisole sulfate |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-dichloro-3,5-dimethylphenol |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-diisopropylphenol |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-di-tert-butylphenol |
3.98 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,5-bis(2-methylbutan-2-yl)benzene-1,4-diol |
3.55 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,5-di-tert-butylbenzene-1,4-diol |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-bis-(1,1-dimethylethyl)-2,5-cyclohexadiene-1,4-dione |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-di(butan-2-yl)phenol |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-diaminopyridine |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-di-tert-butyl-4-nitrophenol |
0.11 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-toluenediamine |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
24r,25-dihydroxyvitamin d3 |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-Acetylaminofluorene |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4-(p-nitrophenyl)thiazole |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4,6-dinitrophenol |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4-chloro-5-nitrophenol |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4-chlorobenzothiazole |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-5-nitrophenol |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-6-nitrobenzothiazole |
44.67 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-aminoanthracene |
3.55 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-aminoanthraquinone |
1.26 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-chloro-4-phenylphenol |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-dodecylisoquinolinium tosylate |
4.35 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-ethylphenol |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydrazino-4-(4-aminophenyl) thiazole |
0.4 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydrazino-4-(4-nitrophenyl)thiazole |
1.26 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydrazino-4-phenylthiazole |
10 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydroxyanthraquinone |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-isovaleryl-1,3-indanedione |
56.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-methyl-1-nitroanthraquinone |
2.77 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-methylanthraquinone |
11.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-naphthalenesulfonic acid, 7-amino-4-hydroxy- |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-naphthalenol |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-nitro-1,4-phenylenediamine |
12.59 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-nitrofluorene |
50.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-phenylphenol |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-propenal,3,3-diphenyl- |
56.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-tert-butyl-4-ethylphenol |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-tert-butyl-4-methoxyphenol |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-tert-butyl-5-methylphenol |
5.01 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-(5,5,6-trimethylbicyclo[2.2.1]hept-2-yl)cyclohexanol |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3',4,4'-tetraaminobiphenyl tetrahydrochloride |
2 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3',5,5'-tetraiodothyroacetic acid |
39.04 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3'-diaminobenzidine |
4.47 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3'-dimethylbisphenol a |
11.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3φ,5,5φ-tetrabromobisphenol a |
17.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,4,5-trichlorophenol |
5.01 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,4-dichlorophenol |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,5-dichlorophenol |
11.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,5-dichlorosalicyl-3,4-dichloroanilide |
0.11 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-acetylphenanthrene |
56.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-amino-9-ethylcarbazole hydrochloride |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-hydroxybenzophenone |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-hydroxy-n-(3-nitrophenyl)naphthalene-2-carboxamide |
0.28 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-hydroxy-n-phenylaniline |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-methylbenzene-1,2-diamine |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-methylcholanthrene |
25.19 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-methyl-n-phenylaniline |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(1,1,3,3-tetramethylbutyl)phenol |
4.89 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(2-methylbutan-2-yl)phenol |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(3-phenylpropyl)pyridine |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(benzyloxyl)phenol |
7.4 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(butan-2-yl)phenol |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4,4-trifluoro-1-phenyl-1,3-butanedione |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-diaminoazobenzene |
5.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-diaminobenzanilide |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-dichlorodiphenyl sulfone |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-dinitrodiphenylurea |
0.97 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-methylenebis(2-chloroaniline) |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-sulfonylbis[2-(prop-2-en-1-yl)phenol] |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-thiobis(6-tert-butyl-m-cresol) |
3.16 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-thiodiphenol |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,6-dichloro-1,3-benzenediol |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,6-di-tert-butyl-m-cresol |
2.51 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-amino-2,6-dichlorophenol |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-amino-2-nitrophenol |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-amino-4φ-hydroxy-3-methyldiphenylamine |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-benzylphenol |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-chloro-1,2-diaminobenzene |
2 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-chloro-2-cyclopentylphenol |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-chloro-3,5-dimethylphenol |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-chlorophenyl isocyanate |
0.71 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-cumylphenol |
3.55 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4'-demethylepipodophyllotoxin |
2.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-dodecylphenol |
5.01 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-hexyl-4'-cyanobiphenyl |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-hydroxybenzophenone |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-methyl-2,6-dinitrophenol |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-nitroanthranilic acid |
17.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-nitro-n-phenylaniline |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-nitrosophenol |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-octylphenol |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-phenoxyphenol |
47.57 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-tert-butylcatechol |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-tert-butylphenyl salicylate |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
5,7-dichloro-8-hydroxy-2-methylquinoline |
1.38 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
5alpha-dihydrotestosterone |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
5hpp-33 |
2.24 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Busulfan |
2 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
5-nitroacenaphthene |
56.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
6-hydroxy-2-naphthyl disulfide |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-aminoacridine, monohydrochloride, monohydrate |
21.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-anthracenemethanol |
19.95 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-nitroanthracene |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-phenanthrol |
3.55 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
acenocoumarol |
9.32 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aclarubicin hydrochloride |
2.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
acriflavine hydrochloride |
0.44 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Albendazole |
19.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aldrin |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
alizarin |
13.77 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
allylestrenol |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aloe-emodin |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
alpha-amylcinnamyl alcohol |
56.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ambazone |
3.98 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ami-193 |
7.74 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aminoquinuride dihydrochloride |
27.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
amorolfine |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
amsacrine hydrochloride |
56.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
amylmetacresol |
8.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
apigenin |
3.55 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aroclor 1260 |
12.59 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
arotinolol hydrochloride |
27.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
axitinib |
1.09 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
barban |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bardoxolone methyl |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
barium chloride |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
basic blue 7 |
0.05 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bazedoxifene |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
beclazone |
21.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzbromarone |
13.77 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzidine |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzidine dihydrochloride |
17.65 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benziodarone |
4.35 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzoic acid, 2-[(4-chloro-3-methylphenyl)amino]- |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzyldimethyltetradecylammonium chloride dihydrate |
13.77 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzyldodecyldimethylammonium bromide |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzylhydrazine dihydrochloride |
19.95 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
berberine chloride |
3.46 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
betamethasone dipropionate |
19.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bexarotene |
8.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bis(tributyltin)oxide |
0.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisacodyl |
7.74 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Bisphenol A |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol a glycidyl methacrylate |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol af |
5.01 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol b |
10 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol e |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol z |
19.95 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bithionol |
0.97 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bosutinib |
1.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromadiolone |
4.35 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromociclen |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromocriptine |
21.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromocriptine mesylate |
13.5 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromofenoxim |
3.98 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromofos |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromoxynil octanoate |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
broquinaldol |
12.59 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bryostatin 1 |
0.001 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
butylparaben |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. 1040 |
7.74 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. basic orange 2 |
19.95 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. basic red 9 monohydrochloride |
0.56 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. basic violet 14 |
0.87 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. disperse blue 27 |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. solvent yellow 14 |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
calcifediol |
12.27 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
calcipotriene |
21.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
calcitriol |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
candesartan cilexetil |
11.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cannabinol |
1.09 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cantharidin |
0.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
CCCP |
0.25 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
carminomycin |
21.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfenapyr |
0.04 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfenethol |
12.59 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfenson |
44.67 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfluazuron |
12.59 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorophacinone |
3.55 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chloropropylate |
44.67 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chloroxine |
9.75 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chromomycin |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chrysarobin |
30.83 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chrysin |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ciclesonide |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Ciglitazone |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cilnidipine |
12.27 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cinalukast |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
clobetasol |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cloflucarban |
0.44 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
clofoctol |
4.35 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
clonixin |
22.39 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cloxyquin |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
coumatetralyl |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cresyl diphenyl phosphate |
3.55 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
curcumin |
2.51 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
d&c yellow 11 |
0.44 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
danthron |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dantrolene sodium |
3.46 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
darbufelone mesylate |
5.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
deltamethrin |
50.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
deslanoside |
0.44 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
desogestrel |
27.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
devazepide |
10.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dexamethasone valerate |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diacerein |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dianiline |
21.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dibutyltin dilaurate |
27.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dichlofluanid |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dichlorodiphenylsilane |
22.39 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diclazuril |
8.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dicofol |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
N,N'-dicyclohexylcarbodiimide |
0.02 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dienestrol |
8.3 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Diethylstilbestrol |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diethylstilbestrol dipropionate |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
digitoxin |
0.06 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
digoxin |
0.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinex |
0.71 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diniconazole |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinobuton |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinocap |
0.63 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinoterb |
2.24 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diphenan |
19.95 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diphenoxylate hydrochloride |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diphenylcyclopropenone |
27.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diphenylurea |
2.51 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
disperse red 82 |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dithiazanine chloride |
0.15 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dithiazanine iodide |
0.03 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dodecyl gallate |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dodecylparaben |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dodecylphenol |
3.16 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
doramapimod;bibr-796? |
21.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
doramectin |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ebselen |
19.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
emodin |
2.51 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
endosulfan sulfate |
17.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
endrin |
21.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
enterolactone |
10.72 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
eprinomectin (b1a, b1b mixture) |
8.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
equilin |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
estradiol acetate |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethacridine lactate hydrate |
5.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethalfluralin |
44.67 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethanol, 2,2'-((1-methylethylidene)bis((2,6-dibromo-4,1-phenylene)oxy))bis- |
10.97 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethoxazene |
2.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethynodiol diacetate |
21.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
etocarlide |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
everolimus |
27.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ezetimibe |
8.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
famoxadone |
4.47 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenamidone |
19.95 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenarimol |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenchlorphos |
6.15 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fendiline hydrochloride |
9.75 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenhexamid |
17.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenretinide |
4.89 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fentiazac |
19.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenticlor |
5.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenvalerate |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
flopropione |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluazuron |
12.27 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
flubendiamide |
25.33 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
flucythrinate |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Flufenamic Acid |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
flunixin meglumine |
7.4 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluorodifen |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluorosalan |
0.19 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluoxastrobin |
11.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
folpet |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
forchlorfenuron |
1 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
formononetin |
17.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fulvestrant |
5.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
geliomycin |
0.19 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
genistein |
10 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
gentian violet |
0.35 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
gramicidin |
0.04 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
halobetasol propionate |
13.77 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
heptachlor |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Hexachlorophene |
0.63 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
indole-3-pyruvic acid |
11.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
indoxacarb |
15.27 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
iodophthalein |
4.35 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
iodophthalein sodium |
6.9 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
isobutylparaben |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
isodrin |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
isoxaben |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
isoxicam |
2.75 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
israpafant |
27.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
kaempferol |
6.76 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
kepone |
2.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Ketoconazole |
5.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lambda-cyhalothrin |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lanatoside a |
0.14 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lanatoside b |
0.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lanatoside c |
0.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lapachol |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lasalocid sodium |
1.38 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lercanidipine hydrochloride |
8.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lestaurtinib |
5.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lornoxicam |
6.15 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lufenuron |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lynestrenol |
7.4 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lysergide |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
malachite green oxalate |
27.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
malotilate |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
manidipine |
27.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Mebendazole |
2.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mepartricin |
6.9 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mepronil |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mesotrione |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
metanixin |
21.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methfuroxam |
17.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methisazone |
12.59 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Methoxychlor |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyl 2,4-dihydroxy-3,6-dimethylbenzoate |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyl triclosan |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyl violet |
0.44 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyldigoxin |
0.24 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Methylene Blue |
2.75 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methylene blue trihydrate |
4.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyltrioctylammonium trifluoromethanesulfonate |
2.24 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
metochalcone |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mgk-264 |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
miripirium chloride |
8.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mk-2206 |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mometasone furoate |
8.3 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n,n-diethylbenzene-1,4-diamine |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n,n-dimethyl-p-phenylenediamine |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nelfinavir mesylate |
30.83 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Niclosamide |
0.1 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
niflumic acid |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nifuroxazide |
2.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Nimesulide |
4.16 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ninhydrin |
56.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Nitazoxanide |
1.26 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Nitrofurantoin |
8.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nitrovin |
5.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nitroxoline |
19.95 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n-methyl-n,n-dioctyloctan-1-aminium chloride |
10 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nocodazole |
2.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nonylparaben |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
norelgestromin |
19.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
noristerat |
21.82 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n-phenyl-1,4-benzenediamine hydrochloride |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
o,p'-ddd |
19.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
o,p'-ddt |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
osalmid |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ouabain |
0.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
oxyphenisatin acetate |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
p,p'-ddd |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
p,p'-dde |
44.67 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
p,p'-ddt |
30.83 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
palmatine chloride hydrate |
12.59 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
p-benzoquinone dioxime |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
penfluridol |
27.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2',4,4',5-pentabromodiphenyl ether |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pentabromophenol |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Pentachlorophenol |
8.9 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pentylparaben |
14.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
perfluorooctanesulfonamide |
2.51 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenmedipham |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenol, 4,4'-butylidenebis[2-(1,1-dimethylethyl)-5-methyl- |
7.08 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenol, 4-methyl-, reaction products with dicyclopentadiene and isobutylene |
8.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenolphthalein |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenoxybenzamine hydrochloride |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenyl isothiocyanate |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phloretin |
11.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
picoxystrobin |
1 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
picropodophyllin |
0.05 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pinacyanol |
0.02 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pirarubicin |
0.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Piroxicam |
5.88 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
polyethylene glycol (9z)-9-octadecenyl ether |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
polyoxyethylene(10)nonylphenyl ether |
4.89 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
p-phenylazophenol |
10 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
prodiamine |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
profenofos |
6.15 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
proflavin hemisulfate |
3.46 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
proflavin hydrochloride |
3.55 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
profluralin |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
propan-2-yl (2r,4s)-4-{acetyl[3,5-bis(trifluoromethyl)benzyl]amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate |
4.47 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
propyl gallate |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
propylparaben |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
proscillaridin |
0.07 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyraclostrobin |
1.26 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyridate |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyrinuron |
28.18 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyrvinium pamoate |
0.17 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
quercetin |
3.16 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
quercetin dihydrate |
2.95 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rac benidipine hydrochloride |
30.83 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rafoxanide |
1.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
raloxifene |
17.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
raloxifene hydrochloride |
7.94 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
resveratrol |
3.71 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Rhein |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
riboflavin |
11.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rifampicin |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rifapentine |
3.88 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rimonabant |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Rotenone |
0.01 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
salicylanilide |
3.98 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
siduron |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
silwet l77 |
8.91 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sodium (4-fluoro-2-{[(1s)-1-phenylpropyl]carbamoyl}phenyl)(quinolin-8-ylsulfonyl)azanide |
11.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sodium 2-phenylphenate tetrahydrate |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sodium bithionolate |
0.89 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sodium warfarin |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sofalcone |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sorafenib |
1.23 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sp600125 |
1.55 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
spiperone |
3.46 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
su-5416 |
13.77 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sulfanitran |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
surinabant |
19.95 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tamibarotene |
13.77 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tamsulosin hydrochloride |
30.83 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tau-fluvalinate |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenidap |
15.85 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenonitrozole |
0.56 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenovin-1 |
3.88 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenoxicam |
6.6 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tert-butyl 4-hydroxybenzoate |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetra-aminopyrimidine sulfate |
25.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetrabromophenolphthalein ethyl ester |
26.55 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetrabutyltin |
11.22 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetradecylpyridinium bromide |
17.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetradifon |
17.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetraiodoethene |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetra-n-octylammonium bromide |
0.13 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetraoctylphosphonium bromide |
0.32 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetrasul |
2.51 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
thidiazuron |
6.31 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
thiram |
24.49 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tibrofan |
0.87 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tioxidazole |
15.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Tipranavir |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tolclofos-methyl |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Tolfenamic Acid |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
toluidine blue |
4.89 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tolvaptan |
19.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
transfluthrin |
19.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tribenoside |
11.73 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tribromosalan |
0.97 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltetradecylphosphonium chloride |
1.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltin benzoate |
0.5 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltin chloride |
0.89 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltin methacrylate |
0.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tricirbine |
0.49 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triclabendazole |
5.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triclocarban |
0.17 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triclosan |
6.15 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triethoxy(2-methylpropyl)silane |
35.48 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triethyltin bromide |
0.2 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trifluralin |
39.81 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trihexyltetradecylphosphonium bromide |
0.45 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trihexyltetradecylphosphonium chloride |
0.89 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trihexyltetradecylphosphonium dicyanamide |
0.89 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trihexyltetradecylphosphonium hexafluorophosphate |
1.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyl phosphate |
1.26 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenylethylene |
31.62 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyltin acetate |
1.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyltin fluoride |
1.78 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyltin hydroxide |
1.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tris(2,3-dibromopropyl) phosphate |
50.12 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Tyrothricin |
0.24 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tyrphostin 23 |
17.34 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
vatalanib |
30.83 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Verteporfin |
8.69 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
zafirlukast |
13.77 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
zearalenone |
5.84 |
|
human |
HepG2 |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(1,1,3,3-tetramethylbutyl)phenol |
42.24±3.43 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(1'-ethyl-6,7-dihydro-5h-spiro[furo[2,3-f]indole-3,4'-piperidin]-5-yl)[2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl]methanone hydrochloride |
40.87±16.01 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(2-ethyl-4-{[(4-{[4-(4-methoxyphenyl)piperazin-1-yl]methyl}-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]sulfanyl}phenoxy)acetic acid |
23.10±15.57 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(2-nitro-1-propenyl)benzene |
25.94±8.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(5-chloro-2-hydroxyphenyl)phenylmethanone |
25.43±21.27 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(5s,8s)-5-(3,4-dichlorophenyl)-8-(methylamino)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide |
35.72±5.79 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
(acryloyloxy)(tributyl)stannane |
8.49±2.50 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Diethylstilbestrol |
42.80±10.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,1,1-trichloropropanone |
23.74±29.59 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,1,2-trimethyl-1h-benzo[e]indole |
34.91±8.48 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,1':3',1''-terphenyl |
29.58±27.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,2,5,6,9,10-hexabromocyclododecane |
32.03±16.51 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,2-phenylenediamine |
17.85±6.50 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,2-phenylenediamine dihydrochloride |
14.22±2.30 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3,5-tris(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-1,3,5-triazinane-2,4,6-trione |
26.79±25.28 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3-didecyl-2-methylimidazolium chloride |
26.25±3.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3-diiminobenz(f)isoindoline |
26.72±23.58 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,3-diphenyl-1,3-propanedione |
39.83±14.21 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,4-diaminoanthraquinone |
1.24±0.76 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,4-dihydroxyanthracene-9,10-dione |
4.81±8.07 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,4-naphthalenediamine |
22.71±8.75 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1,8-dihydroxy-4,5-dinitroanthraquinone |
5.69±2.62 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
10-chloro-9-anthraldehyde |
24.28±28.84 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Mito-4509 |
35.48±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
17alpha-ethinylestradiol |
18.39±1.50 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-amino-2,4-dibromoanthraquinone |
27.37±4.44 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-amino-2-methylanthraquinone |
5.28±3.30 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-decyl-3-methylimidazolium tetrafluoroborate |
16.76±7.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-decyl-3-methylimidazolium trifluoromethanesulfonate |
12.13±3.97 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-dodecyl-3-methylimidazolium hexafluorophosphate |
8.81±2.46 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-fluoro-2,4-dinitrobenzene |
8.30±5.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1h-benzo[de]isoquinoline-1,3(2h)-dione |
5.56±8.92 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1h-indole-2-carboxamide, n-[(3r)-1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- |
17.34±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-hydroxypyrene |
33.55±2.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-isocyanato-3-(trifluoromethyl)benzene |
11.52±3.69 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methyl-3-octylimidazolium hexafluorophosphate |
39.81±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methyl-3-octylimidazolium tetrafluoroborate |
43.42±7.40 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methyl-3-octylimidazolium trifluoromethanesulfonate |
31.62±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-methylpyrene |
32.18±7.36 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-nitronaphthalene |
45.86±14.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
1-nitropyrene |
16.88±4.77 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Edaravone |
25.79±10.10 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-(thiocyanomethylthio)benzothiazole |
30.47±26.36 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2',4,4',5-pentabromodiphenyl ether |
9.11±4.93 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2',6,6'-tetrachlorobisphenol a |
29.74±11.13 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'4,4'-tetrabromodiphenyl ether |
25.56±34.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane |
33.22±24.22 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-dihydroxy-4,4'-dimethoxybenzophenone |
29.81±13.75 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-dihydroxy-4-methoxybenzophenone |
11.08±5.21 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-methylenebis(4-methyl-6-tert-butylphenol) |
3.71±0.47 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2'-methylenebis(ethyl-6-tert-butylphenol) |
5.01±4.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3',4,4'-tetrahydroxybenzophenone |
40.36±8.45 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,4,5-tetrachlorophenol |
11.55±5.42 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,4-trichlorophenol |
41.79±14.43 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,5,6-tetrachlorophenol |
9.20±2.96 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,3,5-trichlorophenol |
27.65±10.40 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4,5-trichlorophenol sodium salt |
27.31±25.25 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-bis(1-methyl-1-phenylethyl)phenol |
43.93±17.40 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-diaminoanisole sulfate |
19.62±19.34 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,4-di-tert-butylphenol |
24.04±16.59 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,5-bis(2-methylbutan-2-yl)benzene-1,4-diol |
34.49±5.88 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,5-di-tert-butylbenzene-1,4-diol |
39.15±15.51 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-diaminopyridine |
20.88±15.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-di-tert-butyl-4-nitrophenol |
0.29±0.30 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,6-toluenediamine |
32.18±7.36 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
24r,25-dihydroxyvitamin d3 |
17.34±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4-(p-nitrophenyl)thiazole |
20.55±21.11 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4,6-dinitrophenol |
28.80±15.58 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4-chloro-5-nitrophenol |
31.27±8.72 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-4-chlorobenzothiazole |
24.04±16.19 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-5-nitrophenol |
52.13±17.74 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-amino-6-nitrobenzothiazole |
22.74±20.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-aminoanthracene |
0.18±0.20 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-aminoanthraquinone |
3.57±2.61 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-chloro-4-phenylphenol |
31.76±3.65 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-dodecylisoquinolinium tosylate |
4.94±2.78 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydrazino-4-(4-aminophenyl) thiazole |
3.55±3.86 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydrazino-4-(4-nitrophenyl)thiazole |
7.90±5.75 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydrazino-4-phenylthiazole |
21.46±17.61 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydroxy-4-methoxybenzophenone |
50.14±18.89 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-hydroxyanthraquinone |
17.28±6.83 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-isovaleryl-1,3-indanedione |
22.25±11.09 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-methyl-1-nitroanthraquinone |
16.95±14.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-methylanthraquinone |
5.97±0.49 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-naphthalenol |
42.21±19.83 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-nitro-1,4-phenylenediamine |
18.06±14.95 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-nitrofluorene |
38.15±9.22 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-phenylphenol |
53.18±4.32 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-propenal,3,3-diphenyl- |
17.12±23.88 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-tert-butyl-4-methoxyphenol |
36.50±19.25 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2-tert-butyl-5-methylphenol |
40.07±6.50 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3',4,4'-tetraaminobiphenyl tetrahydrochloride |
9.46±4.43 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3',5,5'-tetraiodothyroacetic acid |
26.13±2.13 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3'-diaminobenzidine |
30.66±28.30 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3'-dimethylbisphenol a |
34.35±4.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,3φ,5,5φ-tetrabromobisphenol a |
36.91±12.56 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,4,5-trichlorophenol |
33.82±17.20 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,4-dichlorophenol |
53.88±13.03 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,5-dichlorophenol |
46.90±8.44 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3,5-dichlorosalicyl-3,4-dichloroanilide |
0.38±0.03 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-acetylphenanthrene |
42.21±19.83 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-amino-9-ethylcarbazole hydrochloride |
56.23±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-hydroxy-n-(3-nitrophenyl)naphthalene-2-carboxamide |
1.60±0.26 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-methylbenzene-1,2-diamine |
36.64±11.80 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
3-methyl-n-phenylaniline |
35.48±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(3-phenylpropyl)pyridine |
12.95±6.83 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-(benzyloxyl)phenol |
9.04±8.10 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-diaminoazobenzene |
26.63±12.51 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-diaminobenzanilide |
33.55±2.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-dichlorodiphenyl sulfone |
29.90±2.43 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-dinitrodiphenylurea |
0.70±0.46 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-methylenebis(2-chloroaniline) |
56.23±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-sulfonylbis[2-(prop-2-en-1-yl)phenol] |
24.48±19.89 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-thiobis(6-tert-butyl-m-cresol) |
24.82±11.78 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,4'-thiodiphenol |
24.70±9.79 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,6-dichloro-1,3-benzenediol |
35.72±5.79 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4,6-di-tert-butyl-m-cresol |
45.86±14.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-amino-2,6-dichlorophenol |
29.55±27.78 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-amino-2-nitrophenol |
33.55±2.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-chloro-1,2-diaminobenzene |
11.03±4.37 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-chloro-2-cyclopentylphenol |
33.65±29.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-chlorophenyl isocyanate |
1.56±0.39 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-cumylphenol |
48.02±11.61 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-dodecylphenol |
25.12±21.80 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-hexyl-4'-cyanobiphenyl |
17.52±15.62 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-hydroxybenzophenone |
17.79±28.01 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-methyl-2,6-dinitrophenol |
15.14±6.79 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-nitro-n-phenylaniline |
23.93±7.05 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-octyloxybenzoic acid |
48.02±11.61 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
4-octylphenol |
53.18±4.32 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
5hpp-33 |
29.09±12.18 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Busulfan |
6.15±3.62 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
5-nitroacenaphthene |
24.04±16.19 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
6-hydroxy-2-naphthyl disulfide |
39.81±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
6-nitroquinoline |
44.84±16.33 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9,10-dihydrobenzo[a]pyren-7(8h)-one |
16.82±7.33 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-aminoacridine, monohydrochloride, monohydrate |
8.51±5.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-anthracenemethanol |
21.66±15.72 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-cyanoanthracene |
17.99±5.46 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-nitroanthracene |
33.05±4.21 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
9-phenanthrol |
47.28±10.66 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
acenocoumarol |
4.59±1.82 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
acetaldehyde |
6.65±4.48 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aclarubicin hydrochloride |
6.89±9.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
acriflavine hydrochloride |
3.55±1.14 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Albendazole |
15.46±21.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
alizarin |
11.87±7.79 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
aloe-emodin |
8.43±5.96 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
alpha-1,2,3,4,5,6-hexachlorocyclohexane |
39.81±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
alpha-amylcinnamyl alcohol |
4.83±4.07 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ambazone |
1.98±2.22 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ami-193 |
25.96±12.20 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
amsacrine hydrochloride |
37.65±3.06 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
anthrone |
42.40±11.98 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
apigenin |
28.93±9.26 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
barban |
35.97±7.53 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bardoxolone methyl |
17.41±2.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
basic blue 7 |
1.53±1.42 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
beclazone |
16.28±20.57 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzbromarone |
4.91±1.79 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzidine |
2.51±3.54 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benziodarone |
1.76±0.68 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzoic acid, 2-[(4-chloro-3-methylphenyl)amino]- |
22.71±16.22 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
benzyldodecyldimethylammonium bromide |
18.39±1.50 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
berberine chloride |
6.03±3.78 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bexarotene |
9.08±1.16 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisacodyl |
18.39±13.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Bisphenol A |
37.65±3.06 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol a glycidyl methacrylate |
38.15±9.22 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol af |
37.26±6.70 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol b |
21.75±8.60 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol e |
36.50±19.25 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bisphenol z |
14.71±15.12 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bithionol |
2.47±1.39 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bosutinib |
16.59±11.17 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromadiolone |
3.40±0.83 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromocriptine |
13.20±10.83 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromocriptine mesylate |
12.57±1.60 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromofenoxim |
2.18±0.86 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromofos |
22.65±10.42 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bromoxynil octanoate |
28.63±22.68 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
broquinaldol |
38.61±34.63 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
bryostatin 1 |
0.79±1.07 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. 1040 |
19.72±4.13 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. basic orange 2 |
24.91±21.08 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. basic red 9 monohydrochloride |
4.11±4.24 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. basic violet 14 |
6.84±4.71 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. disperse blue 27 |
32.46±10.39 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
c.i. solvent yellow 14 |
17.04±10.60 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
calcifediol |
14.21±9.57 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
calcipotriene |
17.34±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
calcitriol |
22.41±7.17 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cannabinol |
21.82±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cantharidin |
0.45±0.30 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfenapyr |
0.07±0.01 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfenethol |
18.94±5.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfenson |
23.70±17.18 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorfluazuron |
29.33±1.99 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chlorophacinone |
4.65±4.78 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chloropropylate |
43.84±10.95 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chrysarobin |
19.29±8.27 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
chrysin |
30.60±28.39 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Ciglitazone |
9.92±4.25 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cilnidipine |
14.79±8.07 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cinalukast |
13.54±5.36 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
clobetasol |
19.76±15.65 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
clobetasol propionate |
24.08±9.54 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cloflucarban |
0.58±0.05 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
clofoctol |
15.67±6.04 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
clonixin |
18.31±5.10 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
coumatetralyl |
13.76±8.10 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cresyl diphenyl phosphate |
22.99±9.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
curcumin |
11.60±9.87 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cybutryne |
14.30±16.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
cyhalothrin |
33.80±9.96 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
danthron |
5.97±5.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dantrolene sodium |
15.52±1.78 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
darbufelone mesylate |
7.15±5.41 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
deltamethrin |
39.83±14.21 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
devazepide |
15.63±7.19 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dexamethasone valerate |
23.46±5.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diacerein |
14.17±11.27 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dibutyltin dilaurate |
22.41±7.17 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dichlofluanid |
22.96±29.49 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diclazuril |
5.70±1.94 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dicofol |
24.64±9.27 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Diethylstilbestrol |
25.19±21.68 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diethylstilbestrol dipropionate |
49.29±19.53 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinex |
1.40±0.60 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diniconazole |
36.04±28.56 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinobuton |
5.74±4.21 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinocap |
4.10±2.16 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dinoterb |
0.76±0.45 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diphenan |
84.22±39.58 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diphenoxylate hydrochloride |
19.45±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
diphenylurea |
8.46±2.39 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
disperse red 82 |
11.68±8.76 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dithiazanine chloride |
2.45±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dithiazanine iodide |
0.98±0.16 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
docetaxel |
12.07±4.78 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dodecyl gallate |
48.72±8.30 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
dodecylphenol |
41.11±13.24 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
doramapimod;bibr-796? |
24.08±9.54 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ebselen |
21.42±5.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
emodin |
6.28±4.57 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
endosulfan sulfate |
25.80±10.10 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
eprinomectin (b1a, b1b mixture) |
8.28±2.44 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
equilin |
39.15±15.51 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethacridine lactate hydrate |
10.25±5.58 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethanol, 2,2'-((1-methylethylidene)bis((2,6-dibromo-4,1-phenylene)oxy))bis- |
32.82±2.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ethoxazene |
4.96±3.42 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
etocarlide |
27.65±10.40 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
everolimus |
13.01±7.49 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
exalamide |
29.15±2.37 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
ezetimibe |
16.64±20.07 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
famoxadone |
8.38±6.71 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenamidone |
42.80±10.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenarimol |
33.55±2.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenchlorphos |
20.64±1.68 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenhexamid |
36.72±21.22 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fentiazac |
9.49±7.98 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fenticlor |
13.88±8.84 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluazuron |
9.83±13.60 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
flubendiamide |
12.80±8.15 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
flucythrinate |
43.93±17.40 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Flufenamic Acid |
14.45±4.99 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
flunixin meglumine |
5.77±4.59 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluorodifen |
24.07±14.98 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluorosalan |
0.42±0.48 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fluoxastrobin |
37.94±19.29 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
folpet |
33.72±20.15 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
forchlorfenuron |
2.19±1.97 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
formononetin |
13.20±16.25 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
fulvestrant |
8.84±12.01 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
geliomycin |
0.55±0.31 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
genistein |
33.67±19.54 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
gentian violet |
1.34±0.11 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
glycyrrhetinic acid |
15.55±2.52 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
gramicidin |
0.20±0.21 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
halobetasol propionate |
25.21±7.02 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Hexachlorophene |
1.00±0.74 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
hydroxystilbamidine bis(methanesulfonate) |
13.60±8.28 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
idarubicin hydrochloride |
27.02±10.70 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
indole-3-pyruvic acid |
21.29±17.89 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
indoxacarb |
34.42±5.58 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
iodophthalein |
7.32±0.60 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
iodophthalein sodium |
8.73±1.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
isoxicam |
4.92±0.80 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
israpafant |
23.46±5.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
kaempferol |
24.06±8.76 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
kepone |
10.15±9.25 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lambda-cyhalothrin |
28.18±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lasalocid sodium |
1.30±0.29 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lercanidipine hydrochloride |
27.48±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lestaurtinib |
12.76±2.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lopinavir |
15.42±21.79 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lornoxicam |
3.30±2.52 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
lufenuron |
44.96±7.29 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
malachite green oxalate |
8.67±12.26 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
malotilate |
23.92±29.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
manidipine |
20.91±5.06 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mepartricin |
27.66±4.48 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mepronil |
56.23±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
metanixin |
21.03±1.37 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methisazone |
21.51±9.04 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Methoxychlor |
27.72±10.98 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyl 2,4-dihydroxy-3,6-dimethylbenzoate |
30.57±28.43 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyl triclosan |
45.86±14.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyl violet |
1.73±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methylene blue trihydrate |
7.29±7.49 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
methyltrioctylammonium trifluoromethanesulfonate |
11.36±2.12 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
metochalcone |
25.48±18.19 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mgk-264 |
17.77±25.05 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
miripirium chloride |
19.54±2.25 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
mometasone furoate |
13.96±1.14 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
montelukast sodium |
24.08±9.54 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n,n-diethylbenzene-1,4-diamine |
31.62±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n,n-dimethyl-p-phenylenediamine |
21.66±15.72 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n,nφ-diethylcarbanilide |
13.11±16.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide |
24.04±16.59 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n-cyclohexyl-4-methyl benzenesulfonamide |
38.09±25.65 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nelfinavir mesylate |
8.68±12.24 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Niclosamide |
0.44±0.27 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
niflumic acid |
6.71±1.14 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nifuroxazide |
6.71±1.54 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Nimesulide |
2.74±0.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Nitazoxanide |
6.94±4.36 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Nitrofurantoin |
7.26±6.35 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nitrovin |
16.39±1.33 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
nitroxoline |
72.33±39.13 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n-methyl-n,n-dioctyloctan-1-aminium chloride |
19.58±4.89 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
n-nitroso-n-methyl-4-nitroaniline |
20.04±16.60 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
norelgestromin |
13.37±12.30 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
o,p'-ddd |
24.18±14.72 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
osalmid |
30.03±21.28 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
oxyphenisatin acetate |
20.64±1.68 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
p,p'-ddd |
42.21±19.83 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
palmatine chloride hydrate |
1.37±0.70 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
penfluridol |
23.24±6.57 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
2,2',4,4',5-pentabromodiphenyl ether |
32.91±2.23 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pentabromophenol |
4.98±2.48 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Pentachlorophenol |
4.17±0.75 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
perfluorooctanesulfonamide |
1.47±0.10 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenazopyridine hydrochloride |
23.75±1.93 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenmedipham |
19.38±9.11 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenol, 4,4'-butylidenebis[2-(1,1-dimethylethyl)-5-methyl- |
21.10±18.22 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenol, 4-methyl-, reaction products with dicyclopentadiene and isobutylene |
0.11±0.07 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phenolphthalein |
39.48±16.93 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
phloretin |
10.60±4.98 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
picoxystrobin |
14.60±4.70 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pinacyanol |
0.04±0.01 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pioglitazone hydrochloride |
8.90±9.20 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pirarubicin |
0.03±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Piroxicam |
4.79±1.53 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
polyethylene glycol (9z)-9-octadecenyl ether |
40.87±13.08 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
prodiamine |
25.42±11.69 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
profenofos |
13.19±3.19 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
proflavin hemisulfate |
11.60±5.45 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
proflavin hydrochloride |
15.91±5.23 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
profluralin |
25.06±35.43 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyraclostrobin |
9.04±1.89 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyridate |
50.45±8.18 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyrinuron |
25.79±10.10 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
pyrvinium pamoate |
1.03±0.26 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
quercetin |
15.14±6.79 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
quercetin dihydrate |
5.83±4.93 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rafoxanide |
1.86±0.83 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
raloxifene |
22.40±24.05 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
raloxifene hydrochloride |
20.94±7.23 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Rhein |
11.58±4.85 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
riboflavin |
31.27±8.72 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rifampicin |
6.15±2.20 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rifapentine |
0.62±0.55 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rimonabant |
17.45±2.83 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Rotenone |
0.20±0.30 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
salicylanilide |
29.09±12.18 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
selenious acid |
44.11±26.85 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
siduron |
43.93±17.40 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
silwet l77 |
14.31±2.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
rapamycin |
20.64±1.68 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sodium (4-fluoro-2-{[(1s)-1-phenylpropyl]carbamoyl}phenyl)(quinolin-8-ylsulfonyl)azanide |
35.85±20.20 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sodium warfarin |
35.48±0.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sofalcone |
19.54±2.25 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sorafenib |
2.25±0.63 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sp600125 |
21.13±2.91 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
spiperone |
2.92±0.24 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
su-5416 |
11.01±1.78 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
sulfanitran |
19.54±2.25 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
surinabant |
34.31±22.53 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
talniflumate |
15.95±6.68 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tamibarotene |
9.06±6.66 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tamsulosin hydrochloride |
25.14±8.04 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenidap |
21.05±7.88 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenonitrozole |
0.68±0.45 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenovin-1 |
18.39±1.50 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tenoxicam |
4.23±3.79 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tert-butyl 4-hydroxybenzoate |
50.76±9.48 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetra-aminopyrimidine sulfate |
42.14±30.55 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetrabromophenolphthalein ethyl ester |
13.85±0.94 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetrabutylphosphonium chloride |
15.30±5.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetradecylpyridinium bromide |
33.55±2.73 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetradifon |
12.05±6.57 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetraiodoethene |
22.56±14.37 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tetraoctylphosphonium bromide |
6.82±2.23 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
thidiazuron |
4.56±2.78 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
thiram |
16.51±20.26 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tibrofan |
16.96±6.90 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tioxidazole |
13.02±1.06 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Tipranavir |
29.15±2.37 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tolclofos-methyl |
31.23±19.01 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Tolfenamic Acid |
14.81±4.38 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tolvaptan |
17.41±2.00 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tribromosalan |
0.55±0.36 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltetradecylphosphonium chloride |
7.66±0.50 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltin benzoate |
5.33±4.70 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltin chloride |
8.95±1.03 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tributyltin methacrylate |
12.76±2.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triclabendazole |
15.55±2.52 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triclocarban |
0.17±0.10 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triclosan |
15.17±13.52 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triethyltin bromide |
0.56±0.21 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trifluralin |
32.62±23.13 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trihexyltetradecylphosphonium bromide |
18.82±4.25 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trihexyltetradecylphosphonium chloride |
30.31±8.97 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
trihexyltetradecylphosphonium dicyanamide |
31.02±11.67 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyl phosphate |
28.93±9.26 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenylethylene |
15.24±11.48 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyltin acetate |
24.13±10.14 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyltin fluoride |
6.17±2.51 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
triphenyltin hydroxide |
14.83±5.12 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
tris(2,3-dibromopropyl) phosphate |
43.95±10.68 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Tyrothricin |
0.66±0.39 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
vatalanib |
20.73±14.69 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
Verteporfin |
21.83±7.79 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
zafirlukast |
3.43±1.47 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
zearalenone |
21.97±1.79 |
|
rat |
hepatocytes |
MMP assay |
decrease |
Positive |
IC50 |
163 |
glyceraldehyde 3-phosphate |
2.5mM |
|
|
|
|
decrease |
Positive |
|
162 |
dihydroxyacetone phosphate |
|
|
|
|
|
decrease |
Positive |
|
162 |
Clofarabine |
|
|
|
|
|
|
Positive |
|
284 |
Acetaminophen |
> 200 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Acetylsalicylic acid |
335.5 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
alpidem |
83.7 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Amantadine |
261.2 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Ambroxol |
> 200 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Amiodarone |
2.6 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Amoxicillin |
> 400 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Ampicillin |
> 400 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Antipyrine |
300 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Arsenic trioxide |
237.9 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Biotin |
4.3 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
lumiracoxib |
> 400 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
bisacodyl |
312.4 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
estradiol acetate |
> 200 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Bupivacaine |
258.2 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Busulfan |
483.1 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Butein |
> 200 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Caffeine |
> 400 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Capsaicin |
275 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Carbamazepine |
66.9 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Cefixime |
> 400 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Chlorambucil |
> 200 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Ciprofloxacin |
> 400 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Clodronate |
> 400 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Clotrimazole |
23.9 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
curcumin |
> 200 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
dexamethasone valerate |
> 200 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Diazoxide |
> 200 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Diclofenac |
137.9 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Diflunisal |
17.9 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Doxorubicin |
8.9 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
erlotinib |
195.9 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Fluconazole |
512.7 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Flufenamic Acid |
42.5 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Flutamide |
27 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
gefitinib |
9.6 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
genistein |
150.6 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Glimepiride |
94.6 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Gossypol |
1 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Ibuprofen |
355.9 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Imatinib |
25.7 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
imipramine |
74.8 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Indomethacin |
443.2 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Isoniazid |
504.6 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Ketoconazole |
243 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Lamivudine |
347.2 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Lidocaine |
339.5 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Lonidamine |
138.1 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
lovastatin |
43.6 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
lumiracoxib |
148.8 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Manganese |
> 800 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Mefenamic acid |
49.7 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Metformin |
388.4 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Mitomycin |
> 200 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Mitoxantrone |
7 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Nicotine |
> 400 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
nifuroxazide |
388.2 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Nimesulide |
10.1 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Nitrofurantoin |
442.5 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Perhexiline |
3.2 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Piroxicam |
101.7 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
pravastatin |
> 200 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
propylparaben |
162.8 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Pyrazinamide |
> 400 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
resveratrol |
395.4 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
rifampicin |
> 800 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
ritonavir |
24.8 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Salicylic acid |
304.3 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Simvastatin |
76.5 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
sorafenib |
0.5 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Sulindac |
> 200 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Tamoxifen |
2.9 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Tolcapone |
3.9 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Tolfenamic Acid |
263.8 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Troglitazone |
3.4 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Valproic Acid |
267.2 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Zidovudine |
416.1 µM |
30 mins |
mouse |
liver mitochondria |
Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) |
decrease |
Positive |
EC20 |
36 |
Amiodarone |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Amiodarone |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
Chlorpromazine |
100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Cyclosporin A |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
imipramine |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Maprotiline |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Rotenone |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Tamoxifen |
100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Troglitazone |
10 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
atorvastatin |
100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
Cerivastatin |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
lovastatin |
100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
Simvastatin |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Decrease |
Positive |
MEC |
306 |
tetracyclines |
|
|
|
|
|
decrease |
Positive |
|
307 |